ReviewBreast (Edinburgh, Scotland)2026
Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: a systematic scoping review.
Review in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeoadjuvant chemotherapy (NACT) is increasingly used in early breast cancer treatment and responses are highly variable. Accurate monitoring of tumour response is crucial for enabling precise surgical de-escalation, yet current methods are inadequate. This systematic scoping review explores emerging technologies for predicting, monitoring, and diagnosing pre-operative breast cancer response to NACT.
methodsA search of Embase, Medline, PubMed, and Cochrane databases was conducted until January 26, 2024. Studies investigating ability to detect tumour response during or after NACT, and prior to surgery, were included, and placed into 12 technology categories. Those investigating novel technologies were further categorised by Technology Readiness Level.
resultsFrom 2497 studies, 1329 met the inclusion criteria. 479/1329 (36 %) investigated conventional imaging; 19 % (253) investigated MRI, 5 % (64) mammography/ultrasound, 0.5 % (6) computed tomography, 0.4 % (5) digital breast tomosynthesis. Established technologies included gene panels (134/1329; 10 %) and post treatment core biopsy 35/1329; (3 %). 107/1329 (8 %) of studies developed nomograms based on routine clinical investigations, and 493/1329 (37 %) correlated established biomarkers e.g. Ki-67 with pathological response. 81 studies (6 %) addressed novel technologies, such as circulating nucleic acids (49/81), diffuse optical imaging (17/81), and elastography (15/81). A Technology Readiness Assessment revealed that all were between Technology Readiness Level 2 (Invention and Research) and 6 (Large Scale).
conclusionsThe majority of current research activity focuses on optimising existing technologies which may never provide the step change in diagnostic accuracy required to advance surgical de-escalation. Research activity should be focused on identifying effective novel technologies and driving translation into the clinical environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.